PMEF
IOVA icon

Point72 Middle East FZE’s Iovance Biotherapeutics IOVA Stock Holding History

Point72 Middle East FZE’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,605
Closed -$83.1K – 1802
2023
Q1 		$83.1K Sell
13,605
-29,660
-69% -$205K ﹤0.01% 1167
2022
Q4 		$276K Buy
+43,265
New +$338K 0.01% 922

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Point72 Middle East FZE's IOVA Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 13,605 shares — an estimated $83.1K sold.

Point72 Middle East FZE first reported a position in IOVA in Q4 2022 and held it in 2 quarters. The position peaked at $276K in Q4 2022. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 13,605 Iovance Biotherapeutics shares in Q2 2023, an estimated $83.1K.
  • Point72 Middle East FZE first reported a position in Iovance Biotherapeutics in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Iovance Biotherapeutics position peaked at $276K in Q4 2022.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.